What it sells
Finding the right cancer drug for each patient.
Business model breakdown
Buyer: who owns the budget?
UnverifiedOncologists and tumor boards at affiliated clinics order the test for patients; patient or clinic pays.
Trigger: what makes them buy now?
UnverifiedPatients with recurrent or treatment-resistant cancer where standard drug options are exhausted and a data-driven ranking of therapies is wanted.
Workflow: what inputs become what output?
Oncologist sends a tumor sample to the Oncobox lab; DNA and RNA are profiled; Oncobox Dx returns a report of molecular abnormalities with a personalized ranking of 170+ targeted and immunotherapy drugs and clinical trial outcomes for the physician or medical board.
Distribution: how it reaches customers
Through affiliated clinics and oncologist consultations; researchers' publications support credibility.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| — | Y Combinator Summer 2017 | — | Y Combinator | ycombinator.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.